Latest Asx Filings News

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.

EPX Limited reported a robust 17% increase in revenue for FY2025, driven by a surge in recurring revenue and strategic expansion into industrial sectors following the Coda Cloud acquisition.

Gale Pacific Limited reported a 1.1% revenue decline to $172 million and a significant net loss of $5.18 million for FY2025, accompanied by a cautious auditor's note on going concern.

Thrive Tribe Technologies has raised approximately $250,000 through a discounted share placement, aiming to bolster its working capital. The move reflects ongoing efforts to support its health and wellness digital platform.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Harvey Norman Holdings Limited has announced a fully franked ordinary dividend of AUD 0.145 per share for the six months ending June 2025, signaling steady returns for shareholders.

Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.

Jupiter Mines has declared a final unfranked dividend of 0.75 cents per share for H2 FY2025, reflecting a solid payout ratio amid fluctuating earnings and Tshipi dividend receipts.

Boss Energy reports a strong financial foundation with positive operating cash flow and a robust balance sheet in FY2025, its first full year of uranium production. Despite a net loss driven by non-cash costs, the company positions itself for growth amid rising uranium prices.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Savannah Goldfields Limited is poised to restart gold production in 2025 at its Georgetown and Agate Creek sites, backed by solid ore reserves and ambitious exploration plans to extend mine life.